Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

Recent clinical trials of the hypoglycaemic sodium-glucose co-transporter-2 (SGLT2) inhibitors, which inhibit renal glucose reabsorption, have reported beneficial cardiovascular outcomes. Whether SGLT2 inhibitors directly affect cardiovascular tissues, however, remains unclear. We have previously re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancini, Sarah J., Boyd, Daria, Katwan, Omar J., Strembitska, Anastasiya, Almabrouk, Tarek A., Kennedy, Simon, Palmer, Timothy M., Salt, Ian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869674/
https://www.ncbi.nlm.nih.gov/pubmed/29588466
http://dx.doi.org/10.1038/s41598-018-23420-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869674/
https://www.ncbi.nlm.nih.gov/pubmed/29588466
http://dx.doi.org/10.1038/s41598-018-23420-4

Ejemplares similares